Iorember F, et al. - Rituximab (RTX) is increasingly being used in place of calcineurin inhibitors (CNI) in pediatric patients with steroid-dependent nephrotic syndrome (SDNS). In this retrospective analysis, the healthcare costs associated with the use of both agents were studied. Although RTX and CNI groups had comparable expenditure, fewer clinical encounters reported in the former group potentially attenuate the burden of healthcare on the patient’s family.